Statement: The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39.
Primary_evidence: Adverse Events 1:   Total: 39/2240 (1.74%)   Supraven.arrhyth. Atrial fibrillation 1/2240 (0.04%)   Cardiac ischemia/infarction 2/2240 (0.09%)   Valvular heart disease 1/2240 (0.04%)   Cardiac General - Other 2/2240 (0.09%)   Endocrine - Other 1/2240 (0.04%)   Ocular - Other 1/2240 (0.04%)   Colitis 2/2240 (0.09%)   Diarrhea 1/2240 (0.04%)   Dysphagia 1/2240 (0.04%)   Gastritis 1/2240 (0.04%)
Secondary_evidence: Adverse Events 1:   Total: 6   Agranulocytosis 0/42 (0.00%)   Anaemia 2/42 (4.76%)   Febrile neutropenia 1/42 (2.38%)   Leukopenia 0/42 (0.00%)   Neutropenia 1/42 (2.38%)   Thrombocytopenia 1/42 (2.38%)   Cardio-respiratory arrest 0/42 (0.00%)   Pericardial effusion 1/42 (2.38%)   Gastric ulcer haemorrhage 0/42 (0.00%)   Melaena 0/42 (0.00%)   Fatigue 1/42 (2.38%)   Multi-organ failure 0/42 (0.00%) Adverse Events 2:   Total: 13   Agranulocytosis 1/61 (1.64%)   Anaemia 1/61 (1.64%)   Febrile neutropenia 0/61 (0.00%)   Leukopenia 2/61 (3.28%)   Neutropenia 2/61 (3.28%)   Thrombocytopenia 1/61 (1.64%)   Cardio-respiratory arrest 1/61 (1.64%)   Pericardial effusion 0/61 (0.00%)   Gastric ulcer haemorrhage 1/61 (1.64%)   Melaena 1/61 (1.64%)   Fatigue 1/61 (1.64%)   Multi-organ failure 1/61 (1.64%)